Ascentage Pharma Group Internat (AAPG) Stock Analysis
Falling Knife setup
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $19.06, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2); Leverage penalty (D/E 1.5): -0.5.
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1... Read more
Hold if already holding. Not a fresh buy at $19.06, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2); Leverage penalty (D/E 1.5): -0.5. Chart setup: Death cross, below all MAs, RSI 25, MACD bearish. Mixed signals. Hold existing position. Score 6.3/10, moderate confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 92d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
Recent Developments — Ascentage Pharma Group Internat
Latest news
- AAPG Reiterates by BTIG -- Price Target Maintained at $48 - GuruFocus — GuruFocus neutral
- BTIG Research Reaffirms "Buy" Rating for Ascentage Pharma Group International (NASDAQ:AAPG) - MarketBeat — MarketBeat positive
- BTIG reiterates Ascentage Pharma stock rating citing trial readouts By Investing.com - Investing.com Canada — Investing.com Canada positive
- Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down - What's Next? - MarketBeat — MarketBeat negative
- Reported Sunday, Ascentage Pharma Presents Preclinical Data At AACR 2026 Supporting Olverembatinib Combinations In Endom — benzinga Apr 20, 2026 positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker·2 ceiling hits
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $19.06, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2); Leverage penalty (D/E 1.5): -0.5. Chart setup: Death cross, below all MAs, RSI 25, MACD bearish. Mixed signals. Hold existing position. Target $41.65 (+118.5%), stop $18.00 (−5.9%), A.R:R 13.4:1. Score 6.3/10, moderate confidence.
Take-profit target: $41.65 (+119.3% upside). Target $41.65 (+118.5%), stop $18.00 (−5.9%), A.R:R 13.4:1. Stop-loss: $18.00.
V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2); Leverage penalty (D/E 1.5): -0.5; Negative momentum.
Ascentage Pharma Group Internat trades at a P/E of N/A (forward -15.5). TrendMatrix value score: 8.7/10. Verdict: Hold.
14 analysts cover AAPG with a consensus score of 4.4/5. Average price target: $48.
What does Ascentage Pharma Group Internat do?Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic...
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.